Finally, we performed Cox’s proportional hazards regression analysis on the data from all patients receiving first induction therapy (55, of whom, 6 received a non-anthracycline-based regimen), and identified high B7-H3 expression on the AML blasts together with age ≥60 years at diagnosis and a WBC of ≥100,000 G/L at diagnosis as independent risk factors for poor outcome (i.e., shorter time to death after diagnosis). Here, CD276 is linked to acute myeloid leukemia.